产品说明书

	同义名 :	-
	CAS号 :	138844-81-2
	货号 :	A612115
	分子式 :	C9H22NNaO7P2
	纯度 :	98% (contains <5% H2O)
	分子量 :	341.211
	MDL号 :	MFCD07197214
	存储条件：	粉末 Keep in dark place,Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Ibandronate Sodium is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis. Low-dose ibandronate (1.25-2 microM) significantly reduced endothelial cell growth, while 2 microM ibandronate also significantly reduced capillary-like tube formation and increased apoptosis of endothelial cells compared to untreated cells. There was no significant difference in activity with doses above 2 microM[3]. Ibandronate (0.5 to 5 mg/day orally or 0.5 to 2 mg every 3 months intravenously) dose-dependently increased bone mineral density, with parallel reductions in the biochemical markers of bone turnover. In preliminary studies in patients with Paget's disease a single intravenous ibandronate dose (2mg) decreased serum alkaline phosphatase levels and urinary markers of bone turnover[4]. Ibandronate effectively inhibits growth of prostate cancer cell lines via inhibition of the farnesyl-IPP-synthase and exhibits synergistic effects with docetaxel[5]. Ibandronate (< 125 mg/kg s.c.) results in a dose dependent increase in bone mineral density (BMD), trabecular bone volume and trabecular number, load to failure (Fmax), and yield load in long bones and vertebrae in ovariectomized rats, and increased trabecular separation in ovariectomized rats is fully prevented by all doses[6].

临床研究
NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02731040	-		Enrolling by invitation	June 30, 2018	-
NCT02520362	-		Active, not recruiting	May 25, 2020	-
NCT02155595	-		Active, not recruiting	August 2018	United States, Michigan ... 展开 >> Henry Ford Medical Center, New Center One Detroit, Michigan, United States, 48202 收起 <<

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	2.93mL 0.59mL 0.29mL	14.65mL 2.93mL 1.47mL	29.31mL 5.86mL 2.93mL

参考文献

[1]Epplen R, Stockle M, et al. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol. 2011 Jan;50(1):127-33. [2]Morgan C, Jeremiah S, et al. Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. Microvasc Res. 2009 Dec;78(3):453-8. [3]Morgan C, Jeremiah S, Wagstaff J. Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. Microvasc Res. 2009 Dec;78(3):453-8 [4]Dooley M, Balfour JA. Ibandronate. Drugs. 1999 Jan;57(1):101-8; discussion 109-10 [5]Epplen R, Stöckle M, Engelmann U, Heidenreich A, Ohlmann CH. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol. 2011 Jan;50(1):127-33 [6]Bauss F, Lalla S, Endele R, Hothorn LA. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 2002 Oct;29(10):2200-8